Business
AZ and Luye Pharma complete agreement for Seroquel
AZ and Luye Pharma complete agreement for Seroquel.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \nRNS Number : 9345S AstraZeneca PLC 28 June 2018 \n\n28 June 2018 13:30 BST\n \nAgreement with Luye Pharma Group for rights to Seroquel and Seroquel XR\nin the UK, China and other international markets completed\n \nAstraZeneca today completed an agreement with Luye Pharma Group, Ltd. (Luye Pharma) for the sale and licence of the rights to Seroquel and Seroquel XR in the UK, China and other international markets, including Brazil, Australia, Saudi Arabia, Mexico, South Korea, Thailand, Argentina, Malaysia and South Africa.\n \nUnder the terms of the agreement, AstraZeneca has received a payment of $260m from Luye Pharma as part of the total $538m consideration. Further payments of $240m and $38m are due in December 2019 and July 2020, respectively, and a milestone payment is also due on the successful transition of certain activities to Luye Pharma. The present value of the upfront and future payments will be reported as Other Operating Income in the Company's financial statements in the second quarter of 2018.\n \nAbout Seroquel\nSeroquel (quetiapine fumarate, immediate release, IR) and Seroquel XR (extended release formulation) are atypical, anti-psychotic medicines with antidepressant properties. The main indications for Seroquel are the treatment of schizophrenia and bipolar disorder. Seroquel XR is also approved in some markets for major depressive disorder and generalised anxiety disorder.\n \nAbout AstraZeneca\nAstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.\n \nFor more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.\n \n\n\n\n\nMedia Relations\n\n\n \n\n\n \n\n\n\n\nKaren Birmingham\n\n\nUK/Global\n\n\n+44 203 749 5634\n\n\n\n\nRob Skelding\n\n\nUK/Global\n\n\n+44 203 749 5821\n\n\n\n\nMatt Kent\n\n\nUK/Global\n\n\n+44 203 749 5906\n\n\n\n\nGonzalo Viña \n\n\nUK/Global\n\n\n+44 203 749 5...